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Amyloid fibrils are physiologically insoluble biophysically specific β-sheet rich structures
formed by the aggregation of misfolded proteins. In vivo tissue amyloid formation is
responsible for more than 30 different disease states in humans and other mammals.
One of these, Alzheimer’s disease (AD), is the most common form of human dementia
for which there is currently no definitive treatment. Amyloid fibril formation by the amyloid
β-peptide (Aβ) is considered to be an underlying cause of AD, and strategies designed to
reduce Aβ production and/or its toxic effects are being extensively investigated in both
laboratory and clinical settings. Transthyretin (TTR) and proteins containing a BRICHOS
domain are etiologically associated with specific amyloid diseases in the CNS and other
organs. Nonetheless, it has been observed that TTR and BRICHOS structures are
efficient inhibitors of Aβ fibril formation and toxicity in vitro and in vivo, raising the possibility
that some amyloidogenic proteins, or their precursors, possess properties that may be
harnessed for combating AD and other amyloidoses. Herein, we review properties of
TTR and the BRICHOS domain and discuss how their abilities to interfere with amyloid
formation may be employed in the development of novel treatments for AD.
Keywords: transthyretin, BRICHOS, Alzheimer’s disease, amyloidosis, neurodegeneration, protein-protein
interactions, chaperones
INTRODUCTION
The amyloidoses are a set of human diseases (and their animal models) in which the precursors,
synthesized as soluble proteins, aggregate and become insoluble under physiologic conditions. They
ultimately form ultrastructural non-branching fibrils 10 nm in diameter with a characteristic cross-
β sheet structure on x-ray diffraction analysis (Glenner, 1980). In tissues the fibrillar aggregates
are seen as extracellular plaque-like structures in the affected organs, which bind the dye Congo
red displaying green birefringence under polarized light (Linke, 2006). Amorphous pre-fibrillar or
“off-pathway” aggregates may be present in the same tissues. Thus far 36 proteins have been noted
to be associated with local or systemic amyloid deposition (Sipe et al., 2016).
In recent years with the ability to make large amounts of recombinant proteins from virtually
any source, it has been noted that many proteins unrelated to disease will form fibrils under
amyloid forming conditions and generate oligomeric species that are cytotoxic in vitro (Bucciantini
et al., 2002). In mammalian cells several examples of physiologically functional amyloids have been
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described (Fowler et al., 2005; Maji et al., 2009). Approximately
∼0.2% of all human proteins (36/20,000) form disease associated
or functional amyloids. Further, in prokaryotes amyloid
structures function as critical elements in biofilm formation
(Blanco et al., 2012). One explanation for the apparent propensity
of only some proteins to be fibrillogenic in vivo is that potentially
amyloidogenic protein domains are “self-chaperoned” in the
context of their intact native conformations. Perhaps evolution
has recognized both the functional usefulness of sequences that
can lead to amyloid formation and the risk of aggregation in
vivo and embedded them in structures that do not allow the
aggregation prone domains to form the homotypic interactions
(“stearic zippers”) required for fibrillogenesis under physiologic
conditions (Goldschmidt et al., 2010). Alternatively it may be
that all proteins have the capacity to form amyloid under the
appropriate conditions with those conditions rarely found in
biology (Dobson, 1999). In eukaryotes, apart from so-called
“normal” amyloids, it is rare for wild type proteins to form
amyloid in vivo unless they undergo some modification, e.g.,
cleavage, as in the case of the Aβ protein precursor (AβPP)
of Alzheimer’s disease (AD) or the serum amyloid A (SAA)
protein precursor in inflammation associated amyloidosis (Haass
and Selkoe, 1993; Kluve-Beckerman et al., 2002). More likely
is the occurrence of variants encoded by a mutation in the
germline gene, as is the case with transthyretin (TTR) and
other precursors responsible for human autosomal dominant
hereditary amyloidoses (Rowczenio et al., 2014). It has also
been argued that evolution has resulted in cells/organisms
constraining the synthesis of some potentially amyloidogenic
molecules to ensure that quantitatively they do not exceed the
critical concentrations sufficient to nucleate the aggregation
process in the presence of adequate cellular chaperone activity
(Tartaglia et al., 2007).
In humans, while many of the amyloidoses are systemic in
distribution, a disproportionate number are represented in the
neurodegenerative diseases associated with aging. The prototype
is AD, a disorder characterized by progressive memory loss
and behavioral changes. Current thinking, based on genetic,
biochemical and in vivo observations, favors the notion that
cleavage fragments of the normal single pass transmembrane
molecule AβPP, i.e., Aβ1–38–43, which are aggregation prone,
form oligomers, which can be shown to be cytotoxic in tissue
culture and synaptotoxic in hippocampal slices (Selkoe and
Hardy, 2016). It is not yet clear if the toxic oligomers are on
the same folding pathway as the fibrils found in the Congophilic
deposits in the brain or whether the fibrils are a less toxic form
of aggregate (Wu et al., 2013). The sequence of AβPP cleavage
followed by aggregation of Aβ fragments is causal in the rare
autosomal dominant forms of AD and is likely to participate
in the pathogenesis of the sporadic disease, but may not be
the sole etiology in the latter. In both forms there appears to
be a multiplicity of contemporaneous or downstream events
involving other cell types (microglia, astrocytes) and proteins,
particularly Tau, which contribute to the development of the
characteristic dementia.
During the last decade studies in transgenic models of human
Aβ deposition have shown that many human genes and the
silencing of a number of mouse genes may have profound
impacts on the pathogenesis of the AD-like changes seen in the
murine models and have suggested roles for these molecules
in inhibiting or facilitating the process of amyloidogenesis in
vivo. The salutary effects of two such genes (TTR and ITMB2)
were quite unexpected since by themselves both protein products
were clearly amyloidogenic and responsible for distinct forms of
clinically relevant human amyloidosis.
Wild type and mutant forms of human TTR cause a spectrum
of human systemic amyloid syndromes including Familial
Amyloidotic Cardiomyopathy (FAC), Familial Amyloidotic
Polyneuropathy (FAP) and Senile Systemic Amyloidosis
(ATTRwt). Mutant forms of ITM2B, encoding the BRICHOS
(see below) domain containing Bri2 protein are etiologic in
Familial British Dementia and Familial Danish Dementia, while
mutations in the gene (SFTPC) encoding another protein with
a BRICHOS domain, lung surfactant C precursor (proSP-C),
cause interstitial lung disease (ILD) with pulmonary amyloid
deposits. We will discuss the available information describing the
biologic and biophysical findings that are apparently involved in
the prevention of one form of amyloid, i.e., that formed by the
Aβ protein seen in the plaques in human AD, by BRICHOS and
TTR, molecules that are direct precursors of other distinct forms
of human amyloidosis and what this may mean in the universe
of protein-protein interactions in complex organisms.
BRICHOS STRUCTURE
The BRICHOS domain is found in several different precursor
proteins. In proSP-C and Bri2 these precursors also contain
segments that are amyloidogenic (Figure 1). The transmembrane
(TM) part of the mature lung surfactant protein C (SP-C) is
an archetypical discordant α-helix composed of a long poly-
Val segment, i.e., the most β-sheet prone sequence possible
(Johansson et al., 1994). As expected from the predicted β-
sheet structure, native SP-C can convert into amyloid fibrils
in vitro (Gustafsson et al., 1999), and expression of the SP-C part
only, i.e., without the rest of proSP-C (including the BRICHOS
domain) in transgenic mice generates severe SP-C aggregation
and toxicity (Conkright et al., 2002). As predicted from the high
α-helix propensity of Leu, poly-Val to poly-Leu replacements
result in a non-aggregating and functional SP-C analog, (SP-
CLeu), which, like SP-C, inserts in surfactant phospholipid
membranes, but unlike SP-C, does not form amyloid fibrils, since
its α-helical conformation is thermodynamically stable (Kallberg
et al., 2001). A synthetic surfactant, presently in clinical trials, has
been developed based on synthetic SP-CLeu, (Johansson et al.,
2003), demonstrating that modulation of β-sheet and amyloid
propensity is a feasible means of designing stable proteins for
biologic drug development.
Under physiological conditions, the poly-Val segment in
native (pro) SP-C is intrinsically prone to form toxic β-sheet
aggregates and amyloid fibrils, and we have proposed that the
BRICHOS domain present in proSP-C prevents the poly-Val
segment from folding into β-sheet aggregates, and promotes
formation of a stable α-helix (Conkright et al., 2002; Johansson
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FIGURE 1 | Architecture of BRICHOS containing proteins. All proteins
that contain a BRICHOS domain have a similar modular structure with a short
N-terminal part in the cytosol, a transmembrane (TM) region, a linker region,
the BRICHOS domain, and in most cases, a C-terminal region. ProSP-C is
depicted in the upper part of the figure and is the only example where the
BRICHOS domain is not followed by a C-terminal region. All other BRICHOS
containing proteins, depicted in the lower part of the figure, (i.e., the Bri family,
chondromodulin, and tenomodulin, gastrokines, and group C, see Hedlund
et al., 2009) contain a C-terminal region of varying length. In spite of their
similar architectures, only the amino acid sequence of the BRICHOS domain is
conserved between BRICHOS containing proteins, while the other parts are
structurally unrelated. The lightning symbols denote the regions that are
amyloidogenic, the TM region in proSP-C and the C-terminal region in Bri2,
see text for details.
et al., 2006). Intriguingly, mutations in the proSP-C BRICHOS
domain result in amyloid formation of SP-C and ILD with lung
fibrosis, apparently the first described amyloid disease that occurs
as result of a mutation in an intramolecular chaperone domain
(Willander et al., 2012a).
The BRICHOS domain is found in species ranging from
humans to simple marine organisms. It is small (about 100
amino acid residues), has a unique fold and is present in a
diverse set of pro-proteins that generate bioactive peptides after
proteolytic processing (Hedlund et al., 2009). BRICHOS has
been identified in 10 human protein families and the name is
derived from BRI2, CHOndromodulin-I and Surfactant protein
C (SP-C). The proteins containing a BRICHOS domain have a
wide range of functions, and disease associations, including ILD
with amyloid deposits (proSP-C), dementia (Bri2), and cancer
(Chondromodulin-I) (Sánchez-Pulido et al., 2002; Willander
et al., 2012a). There are low pairwise sequence identities between
different BRICHOS domain families (∼15–25%) but all have
similar predicted secondary structures. The precursor proteins
have a common overall architecture, and are predicted to be
type II TM proteins (Sánchez-Pulido et al., 2002; Hedlund et al.,
2009; Knight et al., 2013) with the N-terminus located in the
cytosol (Figure 1). All BRICHOS containing proproteins have
a cytosolic segment, a hydrophobic TM region, a linker region
followed by a BRICHOS domain, and a C-terminal region except
proSP-C, in which there is no C-terminal region following the
BRICHOS domain. All the proproteins except proSP-C have a
segment with high β-sheet propensity, the C-terminal region.
In proSP-C the high β-sheet propensity is found in the TM
region (Sánchez-Pulido et al., 2002; Hedlund et al., 2009). In all
BRICHOS containing pro-proteins the regions that are prone
to form β-sheets are well conserved, and are likely to be the
BRICHOS client regions that are destined to aggregate in the
absence of functional BRICHOS.
The only BRICHOS crystal structure thus far determined is
that of proSP-C BRICHOS (pdb code 2yad). It has a unique fold
composed of five β-strands arranged in a mixed anti-parallel and
parallel fashion, and two flanking α-helices (Figure 2). Helix 1
packs against face A of the β-sheet and helix 2 packs against
the opposite side of the β-sheet, face B. Molecular dynamic
simulations suggest that helix 1 can translocate exposing the
underlying face A of the β-sheet. This implicates face A as the
binding site for possible substrates (Willander et al., 2012a), but
direct evidence of binding of any peptide to face A has not been
found. Homologymodels of the human BRICHOS domains from
each family showed that they are compatible with the proSP-
C BRICHOS structure with respect to the secondary structural
elements, but the loop regions are highly variable among different
BRICHOS domains. An interesting observation was that face A of
the proSP-C BRICHOS contains mainly hydrophobic residues,
which are apparently complementary to its hydrophobic target
sequence—the TM region of proSP-C. Bri2, and Bri3 BRICHOS
instead have a face A that contains several residues with charged
side-chains, and the proposed Bri2 and Bri3 BRICHOS target
sequences, i.e., the respective Bri2 and Bri3 C-terminal regions
that are prone to form β-sheets, contain multiple charged
residues. This suggests that the properties of face A reflect its
binding preferences in the respective BRICHOS domain (Knight
et al., 2013). There are only three strictly conserved residues in
all BRICHOS domains, two cysteines and one aspartic acid. The
cysteines form a disulfide bridge in proSP-C BRICHOS and their
strict conservation suggests that a corresponding disulfide bridge
is present in all BRICHOS domains.
TRANSTHYRETIN (TTR) STRUCTURE
In contrast to BRICHOS, which represents a domain common
to a diverse family of proteins, some of which are known to
be amyloidogenic, TTR is a unique human protein synthesized
in hepatocytes, retinal pigment epithelial cells, choroid plexus
epithelium, pancreatic α-cells, Schwann cells, and neurons under
some conditions. It is the major carrier of retinol binding
protein (RBP) charged with retinol in serum and a minor
carrier of the thyroid hormone precursor thyroxine (T4) prior
to its conversion to the physiologically more active tri-iodo—
thyronine (T3) by tissue deiodinases (Buxbaum, 2007). Only a
small fraction of the circulating TTR carries T4 while 25–50% is
loaded with RBP-retinol. However, in cerebrospinal fluid choroid
plexus synthesized TTR is the major T4 carrier. TTR is a non-
disulfide linked homo-tetramer in which the mature polypeptide
monomer, after cleavage of the leader sequence, contains 127
amino acids. The tetramer is thermodynamically and kinetically
quite stable with a Ka = 1.1 × 1024M−3(Hurshman et al., 2004).
The crystal structure shows a twofold axis of symmetry (Blake
et al., 1978). It is assembled as a dimer of dimers around a central
channel, which is primarily hydrophobic and contains the two
T4 binding sites (Figure 3). T4 binding in the first site induces an
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allosteric change that makes the second site less accessible to its
natural ligand (Neumann et al., 2001). While different portions
of the protein bind T4 and RBP, both stabilize the tetrameric
structure reducing its tendency to dissociate (White and Kelly,
2001).
proSP-C BRICHOS IN INTERSTITIAL LUNG
DISEASE
The proSP-C gene (SFTPC) is located on chromosome 8 and
contains 6 exons encoding a 197 amino acid protein. The protein
is expressed exclusively in the secretory pathway of pulmonary
alveolar type II cells (Mulugeta and Beers, 2006). Proteolytic
cleavage of proSP-C eventually generates the 35-residue SP-C,
consisting of an α-helical poly-Val TM region plus an 8-residue
N-terminal segment located outside the membrane (Johansson
et al., 1994, 1995). The SP-C peptide is secreted as part of lung
surfactant, into the alveolar space (Beers et al., 1994; Whitsett
and Weaver, 2002). SP-C is unique in that although the primary
translation product is a TM protein it is ultimately secreted as
a lipophilic, mature peptide (Russo et al., 1999). Mutations in
the proSP-C gene lead to ILD, a form of fibrosis (Nogee et al.,
2001, 2002; Beers and Mulugeta, 2005; Willander et al., 2012a)
with Congophilic deposits containing the mature SP-C segment
(Willander et al., 2012a). Both inherited and spontaneous proSP-
C mutations have been implicated in ILD (Hamvas, 2006) and a
systematic search revealed 91 SFTPC disease-causing mutations
(Litao et al., 2017). Roughly two thirds of the resulting residue
exchanges are localized to the BRICHOS domain, but the most
frequent mutation (I73T) is localized in the linker region in
between the TM region and BRICHOS. A majority of the ILD
associated mutations are located in the linker region or in the
BRICHOS domain, and these mutations are proposed to lead to
amyloid formation of the SP-C peptide (Willander et al., 2012a).
The TM α-helix of SP-C has very high β-sheet propensity, since
it is composed of mainly valine residues (Kallberg et al., 2001;
Johansson et al., 2010; see above under BRICHOS Structure). It
has been hypothesized that proSP-C BRICHOS promotes correct
folding and insertion into the membrane of the α-helical TM part
of SP-C, preventing the formation of amyloid and ILD (Hedlund
et al., 2009; Willander et al., 2012a). Consistent with that notion
is the observation that native SP-C isolated from lung surfactant,
aggregates into amyloid fibrils in vitro that can be visualized
by electron microscopy (EM), but co-incubation with proSP-C
BRICHOS abrogates SP-C fibril formation (Nerelius et al., 2008).
BRI2 IN FAMILIAL BRITISH AND DANISH
DEMENTIA
Integral membrane proteins 2B (ITM2B) and 2C (ITM2C) also
called Bri2 and Bri3 respectively are part of the BRI family. The
Bri2 gene (ITM2B) is located on chromosome 13 and contains
6 exons. The Bri3 gene (ITM2C) is located on chromosome
2 and contains 7 exons. Bri2 and Bri3 proteins share 42%
overall sequence identity, and their BRICHOS domains have 60%
identical residues. The BRI family may be themost ancient family
FIGURE 2 | Structure of the BRICHOS domain. Backbone conformation of
proSP-C BRICHOS (Willander et al., 2012a) with the five β-strands (S1–S5)
and the two α-helices (H1 and H2) labeled. Face A of the β-sheet is localized
toward H1 and face B is localized toward H2.
of BRICHOS containing proteins, considering it has members
in the most ancient species (flies and worms; Sánchez-Pulido
et al., 2002). The Bri2 protein is a 266-residue long, type II TM
proprotein consisting of an N-terminal cytosolic part (residues
1–54), a TM region (residues 55–75), a linker (residues ∼76–
130), a BRICHOS domain (residues∼130–231) and a C-terminal
region (residues 232–266). Bri2 has an N-glycosylation site at
asparagine, Asn170 (Tsachaki et al., 2011), and is expressed
at high levels in brain, heart, placenta, and pancreas (Vidal
et al., 1999). Processing of Bri2 by furin releases a 23-residue
peptide referred to as Bri23 (corresponding to residues 244–
266 of Bri2) from the C-terminal region. Mutations in Bri2
give rise to release of extended, 34-residue, C-terminal peptides,
ABri, or ADan, that deposit primarily in the CNS in two rare
amyloid diseases, familial British dementia (FBD) and familial
Danish dementia (FDD), respectively (Cantlon et al., 2015a).
After the discovery of the pathogenic FBD and FDD mutations
and Bri2 as the precursor to the ABri and ADan peptides
(Vidal et al., 1999, 2000), furin was identified as the major
protease responsible for the proteolytic cleavage releasing the
C-terminal peptides (Kim et al., 1999), but other proprotein-
like convertases may also process Bri2, releasing C-terminal
peptides (Kim et al., 1999; Vidal et al., 2000). Moreover the
Bri2 BRICHOS domain can be shed by ADAM10 cleavage and
released into the extracellular space, but Bri3 is apparently not
processed by ADAM10 (Martin et al., 2008). The remaining
membrane associated N-terminal fragment of Bri2, is cleaved
by intramembranous proteolysis by signal peptide peptidase-like
(SPPL) proteases, SPPL2a and SPPL2b. This cleavage releases
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FIGURE 3 | Model of TTR tetramer. Shown with ligand in T4 binding pocket
(A). Shown with two molecules of retinol binding protein (RBP) charged with
retinol (B) (Monaco, 2002). While there are two potential T4 binding sites,
binding of the first results in an allosteric change restricting access to the
second. In humans, generally only one of the RBP binding sites is occupied.
a Bri2 intracellular domain (ICD) as well as a secreted so
called C-domain (Martin et al., 2008). SPPL cleavage of Bri2
likely takes place secondary to ADAM10 mediated shedding.
Moreover ADAM10 processing is not sequence specific but
rather occurs at specific distances from the plasma membrane
(Sisodia, 1992). Together, the available data are most consistent
with ADAM10 releasing the BRICHOS domain by cleavage in
the linker region of Bri2. See Figure 4 for an overview of Bri2
processing.
FBD is a rare disease that shares many similarities with AD
with memory loss and dementia (Mead et al., 2000). Typical
histological findings are amyloid deposition of ABri, cerebral
amyloid angiopathy (CAA) and neurofibrillary tangles (NFT’s)
(Vidal et al., 1999). FDD shares similarities with FBD but patients
also show cataracts and deafness. Histological findings in FDD
include CAA, NFT’s and hippocampal ADan amyloid plaques
(Vidal et al., 2000). The FBD pathogenic mutation converts the
stop codon in the Bri2 gene to a codon for arginine, extending
the open reading frame to include 11 additional amino acids,
giving rise to the 34 residue long extended peptide, ABri.
The FDD mutation is different and leads to a 10-nucleotide
duplication, causing a frame shift replacing the stop codon of
FIGURE 4 | Proteolytic processing of Bri2. The full-length Bri2 protein is
cleaved by furin resulting in release of the Bri23 peptide, and subsequent
cleavage by ADAM10 releases the BRICHOS domain and generates an
N-terminal fragment (NTF) that can be cleaved by signal peptide peptidase like
(SPPL) proteases into an intracellular domain (ICD) and a released C-domain.
Bri2, extending the peptide to another 34 residue peptide, ADan.
Both ABri and ADan are thus 11 residues longer than the non-
pathogenic Bri23, but the additional residues share no sequence
homology (Cantlon et al., 2015b). Aβ has been found in both
fibrillar and non-fibrillar deposits of ADan in FDD (Tomidokoro
et al., 2005), and Bri2, and/or parts thereof, have been found
to deposit with Aβ plaques in AD (Del Campo et al., 2014).
These observations suggest possible links between the events
underlying the two diseases. It has been suggested that FBD
and FDD are caused by the aggregation of ABri and ADan
respectively, and/or by a loss-of function of mature Bri2 (Cantlon
et al., 2015a). Experimental support for both theories can be
found. Data from FBD-Bri2 and FDD-Bri2 knock-in mice as well
as human patients show a reduction in Bri2 levels (Tamayev et al.,
2010a; Matsuda et al., 2011), and knocking in Bri2 in FDD-Bri2
knock-in mice rescues negative effects on cognition (Tamayev
et al., 2010a,b). Moreover, studies show that ABri and ADan
aggregation in vitro causes cell toxicity (El-Agnaf et al., 2001,
2004) and effects on synaptic plasticity (Cantlon et al., 2015b)
similar to Aβ.
THE TTR AMYLOIDOSES
TTR is encoded by a single gene on chromosome 18 that
encompasses approximately 19 Kb of DNA with 4 exons
included within 7 Kb, 6 Kb of upstream (5′) sequence
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and 6 Kb downstream containing the conventional 3′ non-
coding sequence that allows normal mRNA processing after
transcription. The promoter proximal 2 Kb appears to contain
all the sequences required for tissue specific expression of the
gene (Sasaki et al., 1985; Costa et al., 1986; Sparkes et al., 1987;
Li et al., 2011; Wang et al., 2014). Despite extensive screening
of human populations there have been no reports of a complete
absence of a functional TTR protein. However, mouse knockouts
survive, are fertile but have a persistent behavioral abnormality
with neuronal loss and mild gliosis in the cortex and CA3 region
of the hippocampus (Buxbaum et al., 2014).
Amyloidogenic protein variants causing the autosomal
dominant clinical disorders Familial Amyloidotic
Polyneuropathy (a sensori-motor and autonomic
polyneuropathy) and Familial Amyloidotic Cardiomyopathy
have been found in 77 of the 127 amino acids in the protein
(Figure 5). Forty residues have been found to have a single
amyloidogenic mutation while fifteen have 2, six have 3,
five have 4, and one has 5. Fifty amino acids have none
and 12 mutations have been described that did not lead to
clinically detectable amyloidosis, although two of the involved
residues had both amyloidogenic and non-amyloidogenic
substitutions (Rowczenio et al., 2014) (Figure 5). There is an
increasing frequency of wild type TTR amyloid deposition
in the heart, carpal tunnel and gut associated with increasing
age currently thought to be related to post-synthetic (perhaps
oxidative) changes that may render the wild type protein less
stable although other, as yet undefined, mechanisms may be
responsible. In the case of the mutations it appears that they
all form tetramers which are kinetically or thermodynamically
unstable under physiologic conditions resulting in enhanced
dissociation releasing monomers which are susceptible to
rapid misfolding, aggregation, and fibril formation (Johnson
et al., 2012). These observations suggest that the monomers
functionally “chaperone” each other.
Recombinant TTR monomers (M-TTR) have been
engineered by replacing residues involved in the interaction
between monomers required to form the dimers required
for tetramerization (F87ML110M) (Jiang et al., 2001). While
these monomers can form a functional tetramer they are
highly aggregation prone and have provided a useful model
to examine the process of aggregation and fibril formation.
Such experiments have revealed that aggregation requires the
structured monomer to become denatured prior to misfolding
and fibril formation (Hurshman et al., 2004). Each monomer
contains eight regions of β-sheet, which may explain their
inherent tendency to form the β-sheet rich amyloid fibrils.
Aggregation appears to primarily involve interaction between
the F and H beta strands (Lim et al., 2013). Interestingly murine
TTR, which is 80 percent identical to the human protein, is
orders of magnitude more kinetically stable and is essentially
non-amyloidogenic under physiologic conditions. The crystal
structures of the wild type and mutant human proteins and
the normal mouse protein are very similar (Hörnberg et al.,
2000; Reixach et al., 2008). It is also interesting to note that
mouse Aβ and islet amyloid polypeptide are apparently
non-amyloidogenic.
FIGURE 5 | Ribbon Diagram of TTR Monomer: The figure shows the
location of many of the identified amyloidogenic and
non-amyloidogenic amino acid substitutions, demonstrating that
almost no region of the protein is spared (structure after Blake et al.,
1978).
Tissue culture studies have shown that exposing target cells to
the engineered TTR monomer or amyloidogenic tetramers can
induce cytotoxicity. However, the tetramer has to dissociate to
release monomer, which appears to bind to cells in a manner
consistent with a receptor ligand like interaction, with aggregates
forming on the cell surface (within a 3–6 h period) with cell
death 48–72 h later (Reixach et al., 2004; Manral and Reixach,
2015). Non-amyloidogenic, non-toxic tetramers are endocytosed
directly by the target cells with little evidence of aggregation and
no apparent effect on cell viability or function.
In vivo it appears that both oligomeric and fibrillar TTR
aggregates deposit with an apparent hierarchy of tissue tropism
favored by particular mutants. It has been known for some
time that limited proteolytic digestion may accelerate amyloid
formation by a given precursor and both intact TTR and
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fragments have been found in the tissue deposits with the
relative proportions of each possibly playing a role in the cardiac
deposition phenotype (Thylén et al., 1993; Bergström et al.,
2005). The mechanism of tissue selectivity, i.e., predominantly
peripheral nerve or myocardium, is unclear and may be more
apparent than real since at autopsy deposits of fibrils formed from
the mutant proteins can be found in most tissues. However, it is
possible that different tissues vary in their capacity to digest TTR
or in the nature of their extracellular matrix either of which may
be related to where fibril deposition occurs.
BRICHOS INTERACTIONS WITH
ALZHEIMER’S DISEASE PEPTIDES AND
ITS EFFECTS ON AMYLOIDOGENESIS
Bri2 binds AβPP and modulates its processing leading to a
reduction of secreted Aβ, both in vitro (Fotinopoulou et al.,
2005; Matsuda et al., 2005) and in vivo (Matsuda et al., 2008;
Tamayev et al., 2012), likely because Bri2 restricts the access
of the secretases involved in AβPP cleavage, but it has also
been shown that Bri2 modulates β-secretase levels (Tsachaki
et al., 2013), providing an alternative explanation for how Bri2
affects AβPP processing. Moreover, residues 46–106 (the TM
region and parts of the linker) are apparently responsible for
binding the juxtamembrane and membrane spanning domains
of AβPP (Fotinopoulou et al., 2005), i.e., the BRICHOS domain
is not necessary for Bri2 interactions with AβPP in these
experimental models (Fotinopoulou et al., 2005; Matsuda et al.,
2005). However, an interesting observation is that while the TM
region of AβPP is involved in binding to Bri2 (Fotinopoulou
et al., 2005), the proSP-C BRICHOS domain and linker region are
implicated in correct folding and incorporation of the metastable
TM α-helix of SP-C into the membrane (Willander et al., 2012a).
It is conceivable that the Bri2 linker together with its BRICHOS
domain could have a similar role in incorporating the TM region
of AβPP into themembrane. Bri3, which has been less extensively
studied than Bri2, is expressed mainly in the brain and co-
localizes with AβPP in neurites, and co-immunoprecipitates with
BACE1 (β-amyloid converting enzyme 1). Similarly to Bri2, it
is cleaved by furin (Wickham et al., 2005). Overexpression of
Bri3 reduces cleavage of AβPP, and Bri3 knockdown by RNA
interference results in increased levels of Aβ(Kim et al., 1999).
BRICHOS domains exhibit potent anti-amyloidogenic
chaperone activity for Aβ peptides and are thought to protect
these aggregation prone client peptide sequences from forming
amyloid. The two homolog BRICHOS-containing proteins Bri2
and Bri3 are expressed in the human central nervous system
(CNS) and are of particular interest in relation to AD. A range of
studies suggests that BRICHOS domains can significantly reduce
the level of toxic oligomeric amyloid species in vivo. For example,
co-expression of Aβ1–42 and proSP-C or Bri2 BRICHOS in the
CNS of transgenic Drosophila melanogaster results in delayed
Aβ1–42 aggregation and dramatic improvements in both lifespan
and locomotor function compared to flies expressing Aβ1–42
alone (Hermansson et al., 2014; Poska et al., 2016). Results from
transgenic mice overexpressing Aβ1–42 as a fusion protein with
the Bri2 protein support the possibility that BRICHOS prevents
Aβ toxicity although it only delays amyloid fibril formation. In
this study (Kim et al., 2013), the normal C-terminal peptide
of Bri2, Bri23, was substituted for the Aβ1–42 sequence, which
resulted in generation of free Aβ1–42 by proteolytic release.
Surprisingly, these mice were not cognitively affected, even
though they had high Aβ1–42 expression and eventually
developed amyloid plaques. The authors suggested that high
Aβ1–42 levels and aggregates are not sufficient to induce memory
dysfunction, and that AβPP processing derivatives (which were
obviously not generated from the Bri2-Aβ construct used) are
contributing to the toxicity seen in AβPP transgenic mouse
models (Kim et al., 2013). However, since the Bri2 BRICHOS
domain has been shown to be released from its proprotein
by proteolysis ((Martin et al., 2008), Figure 4), an alternative
explanation for the lack of toxic effects seen in the Bri2- Aβ1–42
expressing mouse model (Kim et al., 2013) could be that liberated
BRICHOS domain delays Aβ aggregation and prevents toxicity,
in a manner similar to that seen in the fly model. This possibility
is further supported by the fact that the Bri2-Aβ expressing
mice formed fewer Aβ oligomers than AβPP expressing mice
(Kim et al., 2013), a finding which is difficult to explain by the
absence of AβPP processing products, but which fits well with
the BRICHOS mechanism of action that involves dramatic
reduction in oligomer formation (see below).
Studies of the kinetics of in vitro Aβ aggregation in the
presence or absence of recombinant proSP-C or Bri2 BRICHOS
show that sub-stoichiometric amounts of BRICHOS domain
significantly slow down fibril formation. It was demonstrated
that BRICHOS inhibits the formation of Aβ1–42 oligomers by
binding to Aβ fibrils and suppressing surface catalyzed secondary
nucleation (Cohen et al., 2015; Figure 6). This redirects the
reaction pathway toward elongation events, thus minimizing
the level of toxic Aβ intermediates. ProSP-C BRICHOS binds
to Aβ fibrils with low nM affinity but does not bind to Aβ
monomers (Cohen et al., 2015). From the X-ray structure of
proSP-C BRICHOS (Figure 2) a mechanism by which BRICHOS
domains may prevent amyloid formation by specifically targeting
a β-hairpin structure was proposed (Willander et al., 2012a), but
it remains to be determined how thismechanism could be applied
in the context of binding to fibrils. The detailed mechanism(s)
used by proSP-C and Bri2 BRICHOS domains to inhibit Aβ
amyloid formation as well as non-fibrillar aggregation apparently
differ (see below) and it is possible that BRICHOS exerts different
effects toward different client peptides as well as depending on its
location, i.e., whether it is intra- or extracellular.
The anti-amyloid activity of BRICHOS extends beyond
the physiological client peptides; recombinant BRICHOS from
proSP-C and Bri2 efficiently delay fibril formation, and more
importantly Aβ1–42 toxicity in vivo in the CNS of Drosophila
(Hermansson et al., 2014; Poska et al., 2016). Endogenous Bri2
BRICHOS is found in amyloid plaques in human AD brains
(Del Campo et al., 2014), BRICHOS binds with high affinity to
Aβ1–42 fibrils in vitro and this dramatically reduces the formation
of toxic Aβ oligomers via a novel and specific mechanism.
Taken together, available results suggest that BRICHOS binds
to Aβ plaques, and thereby shuts down generation of toxic Aβ
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FIGURE 6 | Molecular mechanism of BRICHOS against Aβ42 fibril
formation and toxicity. (A) Aβ42 forms oligomers via a primary nucleation
reaction, which thereafter can convert into fibrils. The fibrils can be elongated
via addition of monomers, while binding of Aβ monomers to the fibril surface
can catalyze formation of oligomers via a secondary nucleation event. (B)
BRICHOS domain binds to the surface of the Aβ fibrils and thereby markedly
reduces the contribution of the secondary nucleation event to the formation of
oligomers (Cohen et al., 2015). See text for details.
species, a mechanism that might be harnessed for AD treatment.
The natural expression of proSP-C is restricted to the alveolar
epithelium, which makes it an unsuitable to target for treatment
of AD and hence ongoing efforts to target AD are mainly focused
on the Bri2 BRICHOS, which is expressed in the CNS.
Bri2 is produced in several peripheral tissues and in the brain,
with significant expression in neurons of the hippocampus and
cerebellum in humans (Vidal et al., 1999; Akiyama et al., 2004).
In vitro, Bri2 BRICHOSwas found to bemuchmore efficient than
proSP-C BRICHOS against both Aβ1–40 and Aβ1–42 fibrillation,
and even in vivo the Bri2 BRICHOS domain seems to inhibit
Aβ1–42 toxicity in Drosophila central nervous system or eyes
more efficiently than pro-SP-C BRICHOS (Willander et al.,
2012b; Poska et al., 2016). Bri2 BRICHOS not only blocks
the secondary nucleation pathway during Aβ1–42 fibrillation,
but also affects the elongation process, which could be the
reason why Bri2 BRICHOS is more efficient than proSP-C
BRICHOS (Arosio et al., 2016). Moreover, proSP-C BRICHOS,
like TTR, (vide infra) has low “general” molecular chaperone
activity (traditionally defined as ability to prevent non-fibrillar
aggregation of destabilized model substrate proteins), while
Bri2 BRICHOS efficiently suppresses aggregation of destabilized
proteins (Poska et al., 2016). Recombinant proSP-C BRICHOS is
predominantly a trimer while Bri2 BRICHOS forms mainly large
complexes (Poska et al., 2016), and therefore it was suggested that
different quaternary structures mediate molecular chaperone and
anti-amyloid activities, respectively, analogous to the situation
for small heat shock proteins (sHSPs) (Roman et al., 2016).
BRICHOS, like many other molecular chaperones, is apparently
“stored” in an inactive form in which the binding surface is
buried, thus avoiding inadvertent interactions with non-clients.
For proSP-C BRICHOS the inactive form is a homotrimer, and
consequently, dissociation of the trimer intomonomeric subunits
should release active BRICHOS. Experimental data support this
possibility; addition of low molecular mass ligands increases
both the ratio of proSP-C BRICHOS monomer/trimer and the
anti-amyloid activity (Biverstål et al., 2015). Bri2, in contrast to
proSP-C, BRICHOS forms mainly polydisperse oligomers but
also monomers and dimers are found, and it remains to be
established which species mediate the ability to prevent Aβ fibril
formation and toxicity.
TTR INTERACTIONS WITH Aβ
CONFORMERS AND ITS EFFECTS ON
IN VIVO AND IN VITRO
AMYLOIDOGENESIS
An in vivo relationship between TTR and AD was suggested
when it was shown that TTR in the CSF could bind Aβ. It was
the third CSF protein to display this activity, the other two being
ApoE and Clusterin (ApoJ) (Ghiso et al., 1993; Strittmatter et al.,
1993; Schwarzman et al., 1994). Early in vitro studies indicated
that TTR could inhibit the formation of Congo red binding fibrils
by Aβ (Schwarzman et al., 2004). In vivo studies demonstrated
that C. elegans transgenic for an Aβ construct driven by the
unc-54 muscle promoter displayed abnormalities in motility
which were abrogated when they were co-transfected with a TTR
cDNA driven by the same promoter (Link, 1995). Tg2576 mice
transgenic for a mutant human Aβ gene had increased TTR
expression in the cerebral cortex and unilateral injection of an
anti-TTR antibody resulted in increased deposition of Aβ on
the ipsilateral compared with the contralateral side of injection
(Stein et al., 2004). Most definitively, when APP23 AD model
mice were crossed with mice over-expressing a wild type human
TTR gene the behavioral and neuropathologic features of Aβ
deposition were suppressed (Buxbaum et al., 2008). Cortical
and hippocampal Aβ1–40/42 deposits were reduced by 60–75%.
The hyper-phosphorylation of Tau seen in the APP23 mice was
diminished and the mice did not develop the defect in spatial
learning seen in mice expressing only human Aβ. When the
same APP23 mice were crossed with Ttr knockout mice amyloid
lesions appeared at 4.5 months of age compared with 9 months
in wild type APP mice. Similar findings were seen in a different
Aβ transgenic strain that were hemizygous for the Ttr knockout,
only with a somewhat less accelerated phenotype, suggesting a
TTR gene dose effect (Choi et al., 2007). The development of
pathology did not seem to be accelerated in the absence of Ttr in
transgenic models that rapidly developed Aβ deposition (Doggui
et al., 2010).
In parallel studies it was shown that 70% of cortical and
hippocampal neurons in human AD brains (vs. 10% in brains of
age matched non-demented subjects) stained with an antibody
specific for TTR as did virtually all the cortical and hippocampal
neurons in the APP23 mice. TTR was also noted to be present in
the Aβ plaques and in vessel walls that contained Aβ deposits.
AβTTR-Aβ complexes were isolated from some human AD
brains and the brains of the APP23 mice (Li et al., 2011).
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MRNA analysis of cultured primary neurons from APP23 mice
revealed that the TTR staining was a function of increased
neuronal synthesis not uptake from the extracellular space (Li
et al., 2011). This was the first demonstration of TTR synthesis
by primary neurons and that neuronal TTR transcription was
increased in the presence of a human AβPP gene. Chromatin
immunoprecipitation (ChIP) studies showed that in neurons (in
contrast to hepatocytes) TTR is up-regulated by the general stress
response regulator Heat Shock Factor 1 (HSF1) which binds
to specific sequences in both the human and mouse promoter
region (Wang et al., 2014). The parallel increases in transcription
of HSP’s 40, 70, and 90, supported the notion that TTR behaves as
a neuronal stress protein. Detailedmolecular studies of CHO cells
stably transfected with either wild type or mutant human AβPP
genes, then transfected with a human TTR construct, revealed
that TTR also bound to the intact APP protein and the C99 β-
secretase cleavage product. The latter interaction (between the
T4 binding pocket of TTR and amino acids A665, T668, and
G659 of C99) resulted in reduced Aβ in the culture medium
presumably because TTR binding interfered with the γ-secretase
cleavage required for the generation of Aβ either because of an
allosteric effect (as suggested for Bri2, vide supra) or the reduction
in phosphorylation of T668 (Li et al., 2016).
Several laboratories have studied the interaction of TTR with
Aβ in vitro in attempts to define the biophysical basis of its
apparent salutary effect in vivo. The earliest studies of the effect of
various TTR variants on in vitro Aβ aggregation were somewhat
difficult to interpret because the only assay utilized was the
inhibition of Congo red binding and the puzzling result that
some TTR variants actually seemed to enhance Aβ aggregation
as measured in this assay (Schwarzman et al., 2004). Since the
molecular nature of the starting Aβ material was not stringently
analyzed the nature of the interaction could only be hypothesized.
Subsequent studies of the inhibition of red blood cell lysis and
neuroblastoma cell apoptosis by a highly aggregation prone (but
not naturally occurring) sub-fragment of Aβ25−35 by TTR also
lacked biophysical or structural studies examining the nature of
the interaction (Giunta et al., 2005).
The first rigorous biophysical analysis of the interaction
utilized TTR isolated from human plasma and a synthetic
form of Aβ1–40 and showed that TTR sub-stoichiometrically
slowed the rate of Aβ aggregation. A mathematical model
suggested that TTR both slowed protofibril elongation and
the lateral association of protofilaments to produce fibrils. The
authors hypothesized that TTR interacted with aggregated rather
than monomeric Aβ (Liu and Murphy, 2006). Subsequent
studies comparing the effects of recombinant TTR and TTR
isolated from plasma were reported as showing that the plasma
protein slowed aggregation but did not inhibit cytotoxicity while
the recombinant protein increased aggregation and was an
effective inhibitor of cytotoxicity. The investigators attributed the
differences in activity to the previously described sulfonylation of
Cys10 in the plasma protein that was not seen in the recombinant
molecule, however there are other possible explanations and a
clear explanation is not yet available (Liu et al., 2009).
Other investigators used 125I-labeled recombinant TTR to
study the interaction between TTR and Aβ1–42 in a competition
binding assay (Costa et al., 2008a). In contrast to the earlier work
they reported that TTR binding was similar with Aβ monomers,
oligomers, and fibrils. They also reported that binding of different
TTR variant tetramers to Aβ was proportional to the stability
of the tetramers, findings that were not consistent with the
results of studies from other laboratories examining the capacity
of tetramers of different stabilities to inhibit fibril formation,
suggesting that binding and the inhibition of aggregation may
not be directly related (Du andMurphy, 2010; Li et al., 2013). The
same group reported that TTR could behave as a disaggregase of
Aβ oligomers and fibrils via its intrinsic cryptic protease activity,
an observation that has not been reproduced by others (Costa
et al., 2008b; Li et al., 2013).
Several laboratories have shown that recombinant M-TTR
bearing mutations (F87ML110M) that do not allow it to form
stable tetramers is a very efficient inhibitor of Aβ aggregation,
appearing to interact with Aβ oligomers in a sub-stoichiometric
fashion. This coupled with the observation that the ability to
inhibit Aβ fibril formation was inversely related to tetramer
(Du and Murphy, 2010; Li et al., 2013) stability suggested
the hypothesis that tetramer dissociation was required for
inhibition of Aβ aggregation, a similar scenario has been shown
for BRICHOS, for which trimer dissociation into monomers
increased the ability to prevent Aβ fibril formation (Biverstål
et al., 2015). However, the ability of highly stable variant TTR
tetramers such as TTR T119M and TTR K15A and murine TTR
(which do not dissociate under the conditions of the in vitro
experiments) to inhibit fibril formation indicates that tetramer
dissociation is not required to inhibit Aβ fibril formation (Li et al.,
2013). Further, although the monomer is a more potent inhibitor
of fibrillogenesis in vitro, in vivo TTR tetramer concentration is
one thousand fold that of the monomer hence unless there is a
biologic compartment enriched in monomeric TTR and Aβ, it is
likely that the tetramer is the active inhibitor in vivo (Sekijima
et al., 2001, Figure 7).
Cross-linking and alanine scanning mutagenesis suggested
that TTR strand G and the EF helix and amino acids L17, L82,
S85, and L110 were directly involved in Aβ binding (Liu et al.,
2009; Du et al., 2012). More detailed precise analysis of binding
using nuclear magnetic resonance spectrometry confirmed the
involvement of amino acids L17 and L110 but not L82 and
S85 (Li et al., 2013). Almost 20 amino acids showed resonance
shifts when TTR interacted with the Aβ monomer all located
in and around the T4 binding site, suggesting that this region
behaves as a predominantly hydrophobic pocket reactive with
small T4-like ligands and hydrophobic stretches of some proteins
(Li et al., 2013). These data were reinforced by experiments
showing that tafamidis, a resveratrol related molecule with high
affinity for the T4 binding site, inhibited the inhibition of fibril
formation by TTR tetramers but had no effect on the inhibition
of fibrillogenesis by the engineered monomeric TTR, which does
not form a T4 binding pocket (Johnson et al., 2012).
Isothermal titration calorimetric (ITC) analysis of the
interaction betweenWT TTR tetramer and the Aβ1–40 monomer
(controlled for the possible self-aggregation of the reactants) had
a KD in the micromolar range and a stoichiometry of 1, differing
considerably from those reported using other techniques (Li
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FIGURE 7 | Model of Interactions between TTR (tetramer) and Aβ1–40/42 and M-TTR (engineered monomer) and Aβ1–40/42. The tetramer clearly binds Aβ
monomers and pulls them out of the aggregation reaction. It is also capable of binding oligomers and fibrils. M-TTR primarily binds oligomers. What is not clearly
shown here is that it is likely that M-TTR is in an oligomeric state when it engages the Aβ oligomers (from Li et al., 2013).
et al., 2013). Interestingly the stoichiometry and KD of the
interaction between the human and mouse tetramers and the
Aβ monomer were very similar even though the human protein
was a much better inhibitor of fibrillogenesis, suggesting, as did
other data, that binding and inhibition of fibril formation are not
equivalent. The stoichiometry of interaction between tetrameric
human TTR and Aβ monomers (approximately 1:1) was much
higher than that determined for the inhibition of fibril formation
by TTR tetramers (sub-stoichiometric,1:40–1:100) indicating
that in the latter experiments it was likely that TTR also interacted
with oligomeric species (Figure 7).
The TTR binding site of Aβ involved the 4G8 epitope,
i.e., amino acids 17–21 (Li et al., 2013). Based on western
blots, which show interaction of oligomeric M-TTR with Aβ
tetramers and octamers, NMR, which showed no resonance
shifts on MTTR-Aβ monomer interaction and ITC, which did
not detect heat gain or release on incubation of MTTR with
monomeric Aβ, the interaction of the recombinant monomeric
MTTR appears to require oligomerization of the monomer
prior to an interaction with Aβ oligomers rather than the Aβ
monomer in a sub-stoichiometric fashion. Similar observations
have been made examining the interaction between M-TTR and
Aβ1–42 using fluorescence correlation spectroscopy (Verghese
et al., 2013). It is possible that some of the discrepancies
in results between the early studies and the most recent
work with respect to the efficacy of inhibition of Aβ by the
various mutant TTR tetramers reflects the presence of variable
amounts of TTR oligomers formed from monomers generated
during the period of incubation of Aβ with different TTR
preparations. It was also quite evident that binding studies using
conformers bound to fixed surfaces gave different results than
experiments performed in liquid phase, e.g., M-TTR bound
Aβ1–42 monomers fixed to nitrocellulose but no interaction was
seen in the liquid phase NMR or ITC experiments (Li et al.,
2013).
A series of experiments examining the mechanism of
inhibition of Aβ1–40/42 cytotoxicity by TTR using both pre-
formed Aβ42 and HypF-N (a model amyloidogenic bacterial
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protein that behaves similarly to Aβ42) cytotoxic aggregates
compared the inhibitory effects of various TTR conformers
and showed that M-TTR was the best with human tetramer
being less effective and the murine tetramer the least inhibitory,
a rank order similar to that seen with inhibition of fibril
formation as an assay (Cascella et al., 2013). More interesting
was the demonstration that the various TTR species all worked
by interacting with the toxic HypF-N oligomeric aggregates
to make them larger and less toxic. In a recent follow up
analysis the inhibitory process utilized by M-TTR was compared
with that seen in the inhibition of HypF-N cytotoxicity by the
extracellular chaperone clusterin and the small heat shock protein
αB-crystallin (Cappelli et al., 2016). Like the chaperones M-
TTR increased oligomer size and reduced the structural order
of the aggregates. These data with HypF-N and correlation
spectroscopy results with Aβ1–42 strongly suggest that M-TTR
does not inhibit aggregation, rather it changes the nature of the
aggregates allowing them to supersaturate the solution forming
non-fibrillar, non-toxic structures. Interestingly while clusterin
and the other “extracellular chaperones” haptoglobin and α2
macroglobulin also inhibit non-fibrillar protein aggregation,
TTR (like proSP-C BRICHOS vide supra) only inhibits
amyloidogenesis. The mechanism of the latter may reflect the
fact that fibrillogenesis requires precise homotypic alignment
of β-strand structures (“stearic zippers”) (Goldschmidt et al.,
2010). It is possible that while pre-amyloid oligomers form
internally homotypic aggregates, those formed by one precursor,
e.g., TTR, are not precisely in register with those of the
second, i.e., Aβ, perhaps forming “hetero-zippers” (Eisenberg, D,
personal communication). The resulting heterotypic aggregates
are less structured and incapable of attaining the order required
for protofibril formation. This would be different in the case
of pairs of amyloid precursors in which cross-seeding occurs
in which the heteromeric oligomeric fit does not disrupt
the parallel or anti-parallel β-sheet structures required for
protofibril formation (Solomon et al., 2007; Oskarsson et al.,
2015).
In summary tetrameric human TTR appears to inhibit Aβ
aggregation by binding Aβ monomers and removing them from
the fibril forming (elongation) pool. It also binds oligomers and
fibrils contributing to the formation of larger, non-cytotoxic
amorphous aggregates. Since the tetramer is far and away
the most prevalent form of TTR in vivo it is likely that this
represents a significant component of its protective effect in
the mouse models. What happens to the TTR-Aβ complexes
is unclear, perhaps as hypothesized elsewhere, it enhances Aβ
transport out of the brain (Alemi et al., 2016). The recent
data that it is also capable of decreasing Aβ production
(at least in cultured cells) suggests a possible additional
mechanism.
While monomeric TTR may not be functionally
protective in vivo the comparison of the biophysics of
its interaction with Aβ and HypF-N with that seen in
molecules long known to be members of the proteostatic
network, i.e., clusterin and αB-crystallin has given
some insight into how those molecules may function
in vivo.
FIGHTING FIRE WITH FIRE: DO AMYLOID
PRECURSORS HAVE THERAPEUTIC
POTENTIAL IN AD?
From the forgoing it is evident that BRICHOS domains and
TTR tetramers and monomers can inhibit Aβ oligomerization,
fibril formation and cytotoxicity in vitro. It also appears
that genetically induced over-expression of the two parent
molecules can suppress or delay the eventual development of the
neuropathologic and behavioral abnormalities seen in transgenic
fly or mouse models of human Aβ deposition (Table 1). At this
moment such genetic approaches are not possible in human
AD. However, it is likely for TTR at least, that human neurons
may already be utilizing this molecule as a defender of neuronal
integrity in the face of proteotoxic and perhaps other forms of
cellular stress. As noted above, the majority (70%) of neurons
in human AD brains make TTR, compared with 10% in age
matched non-demented control brains, a finding also seen in
transgenic models of human Aβ deposition. Further both TTR
and Bri2 have been found in human AD plaques. The latter may
reflect either that they are behaving as co-conspirators or more
likely is that those molecules represent failed (or successful, if
the fibrils are the least toxic form of Aβ aggregates) chaperones.
These observations pose the question does AD represent an age
related failure of host neuronal defense mechanisms? If that is the
case can the failure be overcome therapeutically? While current
approaches to AD focus on reducing Aβ production, might we
do better by enhancing host resistance or some combination of
the two?
Gene Therapy
Direct administration of a TTR or BRICHOS containing gene
to humans is currently not feasible, however it may become
possible to isolate totipotent stem cells from subjects with AD,
differentiate them to neurons or astrocytes, engineer them to
contain a wild type human TTR or BRICHOS containing gene
regulated by either their own or an inducible promoter and
administer those cells to the patient from whom they were
obtained. Currently there are many unknowns surrounding this
approach. It assumes that a mode of administration will be
available to insure that the cells reach the nervous system and
home to regions of pathology. The gene must include all the
regulatory sequences required for tissue specific expression and
protein production in the secretory pathway so that the encoded
protein will be available to interact with Aβ and its oligomers
secreted by the endogenous neurons. If the gene is driven by
an inducible promoter the inducing agent must be able to cross
the blood brain barrier. Further the long term behavior of cells
differentiated from pluripotential precursors is currently unclear.
Protein or Peptide Therapy
A large number of proteins including TTR and BRICHOS and
peptides derived from them have been shown to inhibit Aβ
aggregation in vitro (e.g., Mangrolia et al., 2016). Currently it
is difficult to deliver these molecules to the central nervous
system, although there have been some successes administering
molecules such as insulin by nasal spray (Hölscher, 2014).
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TABLE 1 | Alzheimer’s disease related activities of Transthyretin and
BRICHOS—containing proteins.
Feature Transthyretin (TTR) BRICHOS (Bri2)
Clinical amyloidosis human FAP, FAC, SSA FBD, FDD
Amyloid formation in vitro + +
Protein topology Unique Homotetramer Domain in many proteins
Interaction with Aβ in vitro Monomers, oligomers,
fibrils
+
Transgene interaction with
AD model in vivo
suppresses suppresses
Effect of knockout on AD
model
accelerates ?
Presence human AD
plaques
+ +
Effect of knockout on CNS
function (no AD gene)
Behavioral abnormality ?
Increased neuronal
synthesis AD
+ ?
Inhibits primary nucleation
Aβ
+ −
Inhibits secondary
nucleation Aβ
? +
Inhibits elongation Aβ + +
One way to circumvent the problems inherent in protein or
peptide delivery has been to use Adenoviral, AAV or lentiviral
vectors as carriers for sequences encoding the therapeutic protein
or peptide (e.g., Kim et al., 2004; Bourdenx et al., 2014; Parr-
Brownlie et al., 2015; Blessing and Déglon, 2016; Saraiva et al.,
2016). Vectors have been developed that will preferentially target
neurons although most still require intracerebral inoculation.
This approach may be more appropriate for a BRICHOS
based reagent than for a TTR related molecule since the
quaternary structural demands of the TTR tetramer may be
constraining with respect to having excess monomers available
to misfold and aggregate rather than interact with some form of
Aβ.
A third approach being explored is based on the observation
that both systemic and neuronal TTR production go down
with increasing age and the assumption that maintaining
neuronal TTR production throughout life will continue to make
TTR available to bind Aβ and its soluble aggregates in the
environment in which they appear to be neurotoxic. If small
molecules can be identified which specifically induce neuronal
TTR (or BRICHOS- containing domain) synthesis and can
cross the blood brain barrier after systemic administration,
they might be able to slow or arrest the progression of
neurodegeneration.
All of these approaches present practical problems with
respect to delivery, specificity of the cellular and molecular
targets and intrinsic amyloidogenicity of the therapeutic agent.
In the case of small molecule therapeutics the potential
for off-target or mechanism related toxicities is always an
issue that cannot be ignored. The delivery and specificity
issues are no different than they are for any therapeutic
biological. The intrinsic amyloidogenicity of molecules as TTR
or BRICHOS-containing proteins, whether encoded by a naked
gene, produced by an engineered differentiated pluripotent stem
cell or induced by a small molecule is a real risk. It would
not be good to either enhance amyloid oligomer formation
by endogenously produced Aβ or induce the synthesis of a
sufficient amount of the therapeutic anti-amyloid to exceed the
critical concentration required to nucleate its own fibrillogenesis.
Based on observations in mice carrying many copies of the wild
type human TTR gene with all the known elements required
for tissue specific expression, it appears that neurons regulate
TTR production quite tightly, perhaps precluding the possibility
of local TTR aggregation and oligomer formation even while
systemic amyloid deposition of liver synthesized TTR goes on
(Buxbaum et al., 2008).
In recent years much has been made of the phenomenon
of “templated misfolding” as a mechanism for spreading of
both Parkinson’s and Alzheimer’s diseases (Walker et al.,
2006; Kordower et al., 2008). It has also been possible to
“seed” Aβ aggregation in mice and rats by the intracerebral
or parenteral administration of homologous brain or fibril
fragments (Brouillette et al., 2012; Heilbronner et al., 2013). In
at least one instance the seeding has been inhibited by pre-
incubation with human TTR (Brouillette et al., 2012).
In other systems it has also been possible to nucleate
murine AA amyloid in vivo by the administration of other
amyloid aggregates raising the notion of cross species seeding
by the ingestion of Foie gras (Solomon et al., 2007). We have
described two examples in which two discrete human amyloid
precursors rather than “cross seeding” inhibit the formation
of cytotoxic Aβ aggregates and fibrils in vitro and in vivo in
transgenic murine models of human Aβ deposition. Further
human data suggest that the production of these molecules
is increased in the course of human AD, perhaps in the
context of neuronal defense. We have reviewed the structural
features of these molecules that appear to be responsible for the
“protective” heterotypic interactions that prevent the homotypic
formation of toxic oligomers and fibrils in vivo and speculate
that these interactions may not be coincidental but represent an
evolutionarily conserved mode of neuroprotection.
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